[Psychopathometric double blind study with nicergoline versus placebo in geriatric patients with slight transit syndromes].
A double-blind study was carried out on 56 geronto-psychiatric in-patients who suffered from cerebral metabolic and nutritional disturbances to prove the effectiveness of 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate (nicergoline, Sermion). After a washout-phase of eight days the patients in the verum group received 3 x 1 dragée at 10 mg for a period of 12 weeks. For methodical reasons only patients with slight transit syndromes and, of these, only the first four weeks of examination were included in the present analysis. Thus 8 verum and 9 placebo patients remain whose findings during the trial are recorded in three procedures of capacity and two procedures of self-assessment (syndrome short test, repeating figures and letters, reading letters; scale for general somatic discomfort, scale for vegetative functional disturbances). In the measuring procedures there is a tendency towards improvement under the treatment with nicergline compared with placebo during the first three weeks. But the present results are not sufficient to come to a clear decision on the effectiveness of nicergoline in patients with cerebrovascular insufficiency.
D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004873:Ergolines / Q000627:therapeutic use*; D006801:Humans; D009530:Nicergoline / Q000627:therapeutic use*; D010919:Placebos
D004873:Ergolines; D010919:Placebos; D009530:Nicergoline
Psychopathometrische Doppelblind-Verlaufsstudie mit Nicergolin versus Plazebo bei geriatrischen Patienten mit leichteren Durchgangs-Syndromen.